In a collaborative effort, a team led by dr. Antonios Mikos (Rice University, Texas, US) and involving John Jansen en Jeroen van den Beucken, theme Reconstructive and regenerative medicine, has demonstrated in PNAS, the feasibility of an in vivo bioreactor-based strategy to generate vascularized bony tissue and its use for mandibular reconstruction.The full publication in PNAS can be found via this link.
In more detail, the approach involved the simultaneous placement of polymeric chambers filled with autologous bone graft against sheep ribs and a polymeric space maintainer in a mandibular defect. During the 9-week period following this procedure, vascularized bone formed within the polymeric chamber and a soft tissue envelop formed around the space maintainer in the mandibular defect. Then, the generated vascularized bone in the in vivo bioreactor was harvested, the space maintainer removed, and the harvested bone tissue was used for mandibular reconstruction. This approach combining space maintenance in a mandibular defect and vascularized bone generation in an in vivo (3D-printed) bioreactor resulted in satisfactory surgical outcome in 5 of 6 of the mandibular defects in the used large animal model.
Jeroen van den Beucken
Related news items
Terrestrial bacteria can grow on nutrients from space26 May 2020
Researchers from the Radboudumc describe in an article in Astrobiology that bacteria can survive on an 'extraterrestrial diet', which affected their pathogenic potential.read more
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology researchers from Radboudumc, Bernhoven Hospital and Jeroen Bosch Hospital described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more